ACT NOW
What do we want to achieve?
The human microbiota is a community of microbial cells (bacteria, fungi, viruses) that reside throughout our bodies, but are particularly abundant in the skin and digestive tract. The main objective of Bioithas is to contribute to generating knowledge about the relationship between the intestinal microbiota and health and disease, through:
The development of microbiota biomarkers of a disease.
The creation of food supplements based on probiotics with proven clinical efficacy.
At Bioithas we care about health and, through our products (probiotics and biomarkers) and scientific research, our goal is to improve people's quality of life and well-being.
At Bioithas we care about health and, through our products (probiotics and biomarkers) and scientific research, our goal is to improve people's quality of life and well-being.
We demonstrate its effectiveness
At Bioithas, we believe that this point is essential, which is why we carry out clinical trials in humans that support the efficacy of the consumption of these food supplements in certain pathologies.
One of the biggest problems in the current market for probiotics is the absence of clinical trials in humans to demonstrate their efficacy. For this reason, it is essential to bet on making efforts to provide probiotics, and other food supplements, with scientific evidence that supports the clinical indications attributed to them.
To carry out many of these clinical trials, we work and collaborate with public and private entities and companies, such as hospitals and clinics, universities or laboratories, for the recruitment of volunteers and patients and / or for the performance of clinical analyses.
In the development of each product we have:
Get your B2B license
We own several patents that can be licensed (B2B), developed from our scientific research.
We have been awarded
Awards in all editions of the annual congress
since 2017
Best Start- Up Biotech
2019
Best Stap-Up
2019
Horizon 2020 SME Instrumental Phase
since 2017
Find out all the latest news
